Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024” Report Highlights:
Recent research proved that the genetic makeup of an individual has a significant impact on the overall therapeutic outcome of the administered therapeutic, which has led researchers to follow a more customized approach in vaccine manufacture to provide the best therapeutic output in patients suffering from a complex disease such as cancer. This customized approach would be more specifically targeted according to the patient’s need which is bound to enhance the overall therapeutic outcome.
Currently there are two types of cancer vaccines available - preventive and therapeutic. Therapeutic vaccines treat an existing cancer by enhancing the body’s natural immune system to recognize, target and destroy tumor cells. Provenge for prostate cancer is the only therapeutic vaccine approved for metastatic prostate cancer in the US.
Unlike cancer therapeutic vaccine, a preventive cancer vaccine is given to provide immunity against viruses that might cause cancer. The only preventative vaccines that have been successfully commercialized at a global level are the human papillomavirus vaccine and hepatitis B virus vaccine.
The cancer therapeutic segment is currently anticipated to be worth more than US$ 100 Billion. With rapid advancement in the immunotherapy segment, almost 60% of the market will be dominated by some immunotherapeutic product by 2024, thus forming the backbone of the global cancer therapy market. This presents an excellent opportunity for an innovative product such as the personalized cancer vaccine.
Genetic sequencing of patient’s tumor cell for neo-antigen is a vital step in the manufacture of personalized cancer vaccine. About a decade ago, the cost for genetic sequencing for an individual was highly expensive, costing about US$ 300,000. Fortunately, the advancement in genetic sequencing techniques, emergence of advanced computing and artificial intelligence has made it a very affordable and faster process which is a major driving factor for the personalized cancer vaccine market.
The US is currently the leading market for personalized cancer vaccine, followed by the European Union. The early launch and impressive adoption of existing preventive and therapeutic cancer vaccine indicates that the US is bound to remain the dominant market for at least a decade. The involvement of regions like Japan, South Korea and China indicates it to be a competitive market in the future. Most of the cancer vaccines under development are focused on the treatment of deadly and highly prevalent cancers such as Melanoma, breast cancer, lung cancer, prostate cancer and Cervical Cancer.
KuicK Research Report on the personalized cancer vaccine market provides a detailed insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2024.
“Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024” Report Highlights:
- General Working Mechanism of Personalized Cancer Vaccine
- Relevance of Biomarkers In Personalized Vaccines
- Developmental Cost Analysis of a Personalized Cancer Vaccine
- Advancements in the Personalized Cancer Vaccine
- Personalized Cancer Vaccine Market Analysis by Cancer
Recent research proved that the genetic makeup of an individual has a significant impact on the overall therapeutic outcome of the administered therapeutic, which has led researchers to follow a more customized approach in vaccine manufacture to provide the best therapeutic output in patients suffering from a complex disease such as cancer. This customized approach would be more specifically targeted according to the patient’s need which is bound to enhance the overall therapeutic outcome.
Currently there are two types of cancer vaccines available - preventive and therapeutic. Therapeutic vaccines treat an existing cancer by enhancing the body’s natural immune system to recognize, target and destroy tumor cells. Provenge for prostate cancer is the only therapeutic vaccine approved for metastatic prostate cancer in the US.
Unlike cancer therapeutic vaccine, a preventive cancer vaccine is given to provide immunity against viruses that might cause cancer. The only preventative vaccines that have been successfully commercialized at a global level are the human papillomavirus vaccine and hepatitis B virus vaccine.
The cancer therapeutic segment is currently anticipated to be worth more than US$ 100 Billion. With rapid advancement in the immunotherapy segment, almost 60% of the market will be dominated by some immunotherapeutic product by 2024, thus forming the backbone of the global cancer therapy market. This presents an excellent opportunity for an innovative product such as the personalized cancer vaccine.
Genetic sequencing of patient’s tumor cell for neo-antigen is a vital step in the manufacture of personalized cancer vaccine. About a decade ago, the cost for genetic sequencing for an individual was highly expensive, costing about US$ 300,000. Fortunately, the advancement in genetic sequencing techniques, emergence of advanced computing and artificial intelligence has made it a very affordable and faster process which is a major driving factor for the personalized cancer vaccine market.
The US is currently the leading market for personalized cancer vaccine, followed by the European Union. The early launch and impressive adoption of existing preventive and therapeutic cancer vaccine indicates that the US is bound to remain the dominant market for at least a decade. The involvement of regions like Japan, South Korea and China indicates it to be a competitive market in the future. Most of the cancer vaccines under development are focused on the treatment of deadly and highly prevalent cancers such as Melanoma, breast cancer, lung cancer, prostate cancer and Cervical Cancer.
KuicK Research Report on the personalized cancer vaccine market provides a detailed insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2024.
1. PERSONALIZED CANCER VACCINE: PROMISING CANCER THERAPEUTICS OF THE FUTURE
1.1 The Possibility of a Cancer Vaccine
1.2 Cancer Vaccines - An Insight into its Current Clinical Status
2. GENERAL WORKING MECHANISM OF PERSONALIZED CANCER VACCINE
2.1 Entities of A personalized Cancer Vaccine & Their Respective Roles
2.1.1 Tumor Neo - Antigens
2.1.2 Human Leukocyte Antigen
2.2 Personalized Cancer Vaccine in Action
2.3 Pharmacogenomics towards Genomic Polymorphism
2.4 Somatic Mutations in Cancer Pharmacogenomics
3. RELEVANCE OF BIOMARKERS IN PERSONALIZED VACCINES
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic & Predictive Biomarkers
3.3 Immune Checkpoint Biomarkers
4. MANUFACTURING PROCESS & COST ANALYSIS OF A PERSONALIZED CANCER VACCINE
4.1 Pre - Manufacturing Cost Analysis
4.2 Manufacturing Cost Analysis of Personalized Cancer Vaccine
4.2.1 Capital Cost
4.2.2 Cost of Raw Materials
4.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
4.2.4 Factory & Administrative Overheads
4.2.5 Filling & Packaging
4.3 Personalized Cancer Vaccine Cost per Patient
5. CURRENT MARKET TRENDS & ADVANCEMENTS IN THE PERSONALIZED CANCER VACCINE SEGMENT
5.1 Breakthrough Research Improving the Outcome of Future Personalized Cancer Vaccine
5.2 Rising Investments in the Personalized Cancer Vaccine Market
5.3 Use of mRNA for the Development of Personalized Cancer Vaccine
5.4 Collaborations & Ventures Ensure Stable Funding to the Personalized Cancer Vaccine Market
5.5 Advancement in DNA Sequencing Technology to Drive the Personalized Cancer Vaccine Market
6. GLOBAL - PERSONALIZED CANCER VACCINE MARKET ANALYSIS BY CANCER TYPE
6.1 Melanoma
6.2 Lung Cancer
6.3 Breast Cancer
6.4 Colorectal Cancer
6.5 Leukemia
6.6 Prostate Cancer
6.7 Cervical Cancer
6.8 Glioblastoma (Brain Tumor)
7. NEW AVENUES & OPPORTUNITIES FOR PERSONALIZED CANCER VACCINE DEVELOPMENT
7.1 Commercial Insights into the Personalized Cancer Vaccine Pipeline
7.2 Opportunities in the Emerging Market
8. PORTER’S FIVE FORCE ANALYSIS OF THE PERSONALIZED CANCER VACCINE MARKET
8.1 Bargaining Power of Suppliers
8.2 Bargaining Power of Buyer
8.3 Threats of Substitute Products
8.4 Threat of New Entrants
8.5 Rivalry Among the Existing Competitors
9. DRIVING FACTORS OF THE PERSONALIZED CANCER VACCINE MARKET
9.1 Increasing Need for Personalized Cancer Vaccine Production
9.2 Alarming Increase in the Number of Cancer Incidences
9.3 Cancer Heterogenetic Environment
9.4 High Level of Specificity
9.5 Assistance from Government
9.6 Improvement in Genome Sequencing Techniques
9.7 Robust Clinical Pipeline Under Development
10. MAJOR CHALLENGES TO THE PERSONALIZED CANCER VACCINE MARKET
10.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
10.2 Commercialization Challenges
11. GLOBAL PERSONALIZED CANCER VACCINE MARKET FUTURE OUTLOOK
12. COMPETITIVE LANDSCAPE
12.1 Advaxis Inc.
12.2 Avax Technologies
12.3 BioNtech AG
12.4 Celldex
12.5 CureVac AG
12.6 Genetech
12.7 Genocea
12.8 Gristone Oncology
12.9 ISA Pharmaceuticals
12.10 Merck
12.11 Moderna Therapeutics
12.12 Neon Therapeutics
12.13 Personalis
1.1 The Possibility of a Cancer Vaccine
1.2 Cancer Vaccines - An Insight into its Current Clinical Status
2. GENERAL WORKING MECHANISM OF PERSONALIZED CANCER VACCINE
2.1 Entities of A personalized Cancer Vaccine & Their Respective Roles
2.1.1 Tumor Neo - Antigens
2.1.2 Human Leukocyte Antigen
2.2 Personalized Cancer Vaccine in Action
2.3 Pharmacogenomics towards Genomic Polymorphism
2.4 Somatic Mutations in Cancer Pharmacogenomics
3. RELEVANCE OF BIOMARKERS IN PERSONALIZED VACCINES
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic & Predictive Biomarkers
3.3 Immune Checkpoint Biomarkers
4. MANUFACTURING PROCESS & COST ANALYSIS OF A PERSONALIZED CANCER VACCINE
4.1 Pre - Manufacturing Cost Analysis
4.2 Manufacturing Cost Analysis of Personalized Cancer Vaccine
4.2.1 Capital Cost
4.2.2 Cost of Raw Materials
4.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
4.2.4 Factory & Administrative Overheads
4.2.5 Filling & Packaging
4.3 Personalized Cancer Vaccine Cost per Patient
5. CURRENT MARKET TRENDS & ADVANCEMENTS IN THE PERSONALIZED CANCER VACCINE SEGMENT
5.1 Breakthrough Research Improving the Outcome of Future Personalized Cancer Vaccine
5.2 Rising Investments in the Personalized Cancer Vaccine Market
5.3 Use of mRNA for the Development of Personalized Cancer Vaccine
5.4 Collaborations & Ventures Ensure Stable Funding to the Personalized Cancer Vaccine Market
5.5 Advancement in DNA Sequencing Technology to Drive the Personalized Cancer Vaccine Market
6. GLOBAL - PERSONALIZED CANCER VACCINE MARKET ANALYSIS BY CANCER TYPE
6.1 Melanoma
6.2 Lung Cancer
6.3 Breast Cancer
6.4 Colorectal Cancer
6.5 Leukemia
6.6 Prostate Cancer
6.7 Cervical Cancer
6.8 Glioblastoma (Brain Tumor)
7. NEW AVENUES & OPPORTUNITIES FOR PERSONALIZED CANCER VACCINE DEVELOPMENT
7.1 Commercial Insights into the Personalized Cancer Vaccine Pipeline
7.2 Opportunities in the Emerging Market
8. PORTER’S FIVE FORCE ANALYSIS OF THE PERSONALIZED CANCER VACCINE MARKET
8.1 Bargaining Power of Suppliers
8.2 Bargaining Power of Buyer
8.3 Threats of Substitute Products
8.4 Threat of New Entrants
8.5 Rivalry Among the Existing Competitors
9. DRIVING FACTORS OF THE PERSONALIZED CANCER VACCINE MARKET
9.1 Increasing Need for Personalized Cancer Vaccine Production
9.2 Alarming Increase in the Number of Cancer Incidences
9.3 Cancer Heterogenetic Environment
9.4 High Level of Specificity
9.5 Assistance from Government
9.6 Improvement in Genome Sequencing Techniques
9.7 Robust Clinical Pipeline Under Development
10. MAJOR CHALLENGES TO THE PERSONALIZED CANCER VACCINE MARKET
10.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
10.2 Commercialization Challenges
11. GLOBAL PERSONALIZED CANCER VACCINE MARKET FUTURE OUTLOOK
12. COMPETITIVE LANDSCAPE
12.1 Advaxis Inc.
12.2 Avax Technologies
12.3 BioNtech AG
12.4 Celldex
12.5 CureVac AG
12.6 Genetech
12.7 Genocea
12.8 Gristone Oncology
12.9 ISA Pharmaceuticals
12.10 Merck
12.11 Moderna Therapeutics
12.12 Neon Therapeutics
12.13 Personalis
LIST OF FIGURES
Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 3-3: High Throughput Immune Assessment for Biomarker Discovery
Figure 4-1: General Overview of Personalized Cancer Vaccine Production
Figure 4-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 4-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
Figure 4-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
Figure 4-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
Figure 4-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
Figure 4-7: Gardasil – Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 4-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 4-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
Figure 4-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
Figure 4-11: Gardasil – Manufacturing Cost per single Dose (US$), 2018
Figure 4-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
Figure 4-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
Figure 4-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
Figure 4-15: Gardasil & Gardasil 9 - Cost Analysis (US$), 2018
Figure 5-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
Figure 5-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
Figure 6-1: Alteration in CDKN2A Mechanism
Figure 6-2: Global - Melanoma & Non – Melanoma Cancer Incidence (000’), 2018
Figure 6-3: Global - Melanoma Prevalence by Region (%), 2018
Figure 6-4: Global - Lung Cancer Incidence (in 000’), 2018
Figure 6-5: Global – Lung Cancer Prevalence by Region (%), 2018
Figure 6-6: Global - Breast Cancer Incidence (000’), 2018
Figure 6-7: Global - Breast Prevalence by Region (%), 2018
Figure 6-8: Global - Colorectal Cancer Incidence (000’) 2018
Figure 6-9: Global - Colorectal Cancer Market Size (%), 2018
Figure 6-10: Global - Leukemia Incidence (000’), 2018
Figure 6-11: Global - Leukemia Market Size (%), 2018
Figure 6-12: Global - Prostate Cancer Incidence (000’), 2018
Figure 6-13: Global - Prostate Cancer Prevalence by Region (%), 2018
Figure 6-14: Provenge - Cost Analysis (US$/Month)
Figure 6-15: Global - Cervical Cancer Incidence (000’), 2018
Figure 6-16: Global - Cervical Cancer prevalence by Region (%), 2018
Figure 7-1: Global - Oncology Market Size by Region (%), 2017
Figure 8-1: Porter’s Five Force Analysis - Overview
Figure 9-1: Driving Factors of the Personalized Cancer Vaccine Market
Figure 9-2: Global - Most Common Types of Cancer by Prevalence, 2018
Figure 9-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
Figure 9-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
Figure 10-1: Scientific Limitations in Personalized Cancer Vaccine Development
Figure 11-1: Global - Gardasil Sales Forecast (US$ Billion), 2018 -2024
Figure 11-2: Cervarix – Future Sales Forecast (US$ Billion), 2018 – 2024
Figure 11-3: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2018 – 2024
Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 3-3: High Throughput Immune Assessment for Biomarker Discovery
Figure 4-1: General Overview of Personalized Cancer Vaccine Production
Figure 4-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 4-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
Figure 4-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
Figure 4-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
Figure 4-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
Figure 4-7: Gardasil – Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 4-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 4-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
Figure 4-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
Figure 4-11: Gardasil – Manufacturing Cost per single Dose (US$), 2018
Figure 4-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
Figure 4-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
Figure 4-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
Figure 4-15: Gardasil & Gardasil 9 - Cost Analysis (US$), 2018
Figure 5-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
Figure 5-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
Figure 6-1: Alteration in CDKN2A Mechanism
Figure 6-2: Global - Melanoma & Non – Melanoma Cancer Incidence (000’), 2018
Figure 6-3: Global - Melanoma Prevalence by Region (%), 2018
Figure 6-4: Global - Lung Cancer Incidence (in 000’), 2018
Figure 6-5: Global – Lung Cancer Prevalence by Region (%), 2018
Figure 6-6: Global - Breast Cancer Incidence (000’), 2018
Figure 6-7: Global - Breast Prevalence by Region (%), 2018
Figure 6-8: Global - Colorectal Cancer Incidence (000’) 2018
Figure 6-9: Global - Colorectal Cancer Market Size (%), 2018
Figure 6-10: Global - Leukemia Incidence (000’), 2018
Figure 6-11: Global - Leukemia Market Size (%), 2018
Figure 6-12: Global - Prostate Cancer Incidence (000’), 2018
Figure 6-13: Global - Prostate Cancer Prevalence by Region (%), 2018
Figure 6-14: Provenge - Cost Analysis (US$/Month)
Figure 6-15: Global - Cervical Cancer Incidence (000’), 2018
Figure 6-16: Global - Cervical Cancer prevalence by Region (%), 2018
Figure 7-1: Global - Oncology Market Size by Region (%), 2017
Figure 8-1: Porter’s Five Force Analysis - Overview
Figure 9-1: Driving Factors of the Personalized Cancer Vaccine Market
Figure 9-2: Global - Most Common Types of Cancer by Prevalence, 2018
Figure 9-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
Figure 9-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
Figure 10-1: Scientific Limitations in Personalized Cancer Vaccine Development
Figure 11-1: Global - Gardasil Sales Forecast (US$ Billion), 2018 -2024
Figure 11-2: Cervarix – Future Sales Forecast (US$ Billion), 2018 – 2024
Figure 11-3: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2018 – 2024
LIST OF TABLES
Table 5-1: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 5-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia
COMPANIES MENTIONED
Advaxis Inc., Avax Technologies, BioNtech AG, Celldex, CureVac AG, Genetech, Genocea, Gristone Oncology, ISA Pharmaceuticals, Merck, Moderna Therapeutics, Neon Therapeutics, Personalis
Table 5-1: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 5-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia
COMPANIES MENTIONED
Advaxis Inc., Avax Technologies, BioNtech AG, Celldex, CureVac AG, Genetech, Genocea, Gristone Oncology, ISA Pharmaceuticals, Merck, Moderna Therapeutics, Neon Therapeutics, Personalis
